Overview

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Pudong Hospital
Collaborator:
UTC Therapeutics Inc.
Treatments:
Cyclophosphamide
Fludarabine